Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $33,469.64 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 1,786 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $18.74, for a total value of $33,469.64. Following the completion of the transaction, the chief executive officer owned 339,392 shares in the company, valued at approximately $6,360,206.08. This represents a 0.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Claire Mazumdar also recently made the following trade(s):

• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total transaction of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total transaction of $49,278.63.

Bicara Therapeutics Trading Down 0.2%

BCAX opened at $18.47 on Monday. The company’s fifty day moving average price is $16.47 and its two-hundred day moving average price is $15.82. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $19.71. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.25 and a beta of -0.78.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BCAX. Legal & General Group Plc boosted its holdings in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Bicara Therapeutics in the 4th quarter valued at about $45,000. Finally, Larson Financial Group LLC lifted its position in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares in the last quarter.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BCAX. HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Citigroup started coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Finally, Citizens Jmp assumed coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set a “market perform” rating and a $31.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $28.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.